Medicamen Biotech Limited (MEDICAMEQ) — Capital Reinvestment Ratio

Latest as of March 2022: 2.09x

Medicamen Biotech Limited (MEDICAMEQ) has a Capital Reinvestment Ratio of 2.09x as of March 2022, meaning it reinvests 2% of its operating cash flow (Rs41.09 Million) in capital expenditures (Rs86.08 Million). See Medicamen Biotech Limited free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

2.09x

Capex / Operating Cash Flow

Operating Cash Flow

Rs41.09 Million

INR

Capital Expenditures

Rs86.08 Million

INR

Data as of

Mar 2022

Most recent filing

Medicamen Biotech Limited Capital Reinvestment Ratio (2006–2022)

This chart tracks Medicamen Biotech Limited's Capital Reinvestment Ratio across 13 annual periods.

Annual Capital Reinvestment Ratio for Medicamen Biotech Limited (2006–2022)

Year-by-year Capital Reinvestment Ratio for Medicamen Biotech Limited from 2006 to 2022. For live market cap and broader valuation context, see MEDICAMEQ market cap overview.

Year	Reinvestment Ratio	Operating CF (INR)	Capital Expenditures	YoY Change
2022	2.09x	Rs41.09 Million	Rs86.08 Million	▲ +48.9%
2021	1.41x	Rs127.72 Million	Rs179.66 Million	▼ -52.1%
2020	2.94x	Rs128.02 Million	Rs376.11 Million	▼ -19.4%
2019	3.65x	Rs43.01 Million	Rs156.81 Million	▲ +464.6%
2017	0.65x	Rs35.92 Million	Rs23.20 Million	▲ +494.8%
2016	0.11x	Rs62.06 Million	Rs6.74 Million	▼ -43.1%
2014	0.19x	Rs51.39 Million	Rs9.80 Million	▼ -44.4%
2011	0.34x	Rs113.52 Million	Rs38.93 Million	▼ -89.3%
2010	3.20x	Rs11.00 Million	Rs35.20 Million	▲ +1210.1%
2009	0.24x	Rs83.07 Million	Rs20.29 Million	▼ -82.7%
2008	1.41x	Rs22.70 Million	Rs31.97 Million	▼ -92.8%
2007	19.44x	Rs2.59 Million	Rs50.30 Million	▲ +2501.1%
2006	0.75x	Rs26.02 Million	Rs19.45 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow